Literature DB >> 19349689

NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.

Tadepally Lakshmikanth1, Shannon Burke, Talib Hassan Ali, Silvia Kimpfler, Francesco Ursini, Loredana Ruggeri, Marusca Capanni, Viktor Umansky, Annette Paschen, Antje Sucker, Daniela Pende, Veronika Groh, Roberto Biassoni, Petter Höglund, Masashi Kato, Kazuko Shibuya, Dirk Schadendorf, Andrea Anichini, Soldano Ferrone, Andrea Velardi, Klas Kärre, Akira Shibuya, Ennio Carbone, Francesco Colucci.   

Abstract

NK cells use a variety of receptors to detect abnormal cells, including tumors and their metastases. However, in the case of melanoma, it remains to be determined what specific molecular interactions are involved and whether NK cells control metastatic progression and/or the route of dissemination. Here we show that human melanoma cell lines derived from LN metastases express ligands for natural cytotoxicity receptors (NCRs) and DNAX accessory molecule-1 (DNAM-1), two emerging NK cell receptors key for cancer cell recognition, but not NK group 2 member D (NKG2D). Compared with cell lines derived from metastases taken from other anatomical sites, LN metastases were more susceptible to NK cell lysis and preferentially targeted by adoptively transferred NK cells in a xenogeneic model of cell therapy. In mice, DNAM-1 and NCR ligands were also found on spontaneous melanomas and melanoma cell lines. Interference with DNAM-1 and NCRs by antibody blockade or genetic disruption reduced killing of melanoma cells. Taken together, these results show that DNAM-1 and NCRs are critical for NK cell-mediated innate immunity to melanoma cells and provide a background to design NK cell-based immunotherapeutic strategies against melanoma and possibly other tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19349689      PMCID: PMC2673866          DOI: 10.1172/JCI36022

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

Review 1.  New aspects of natural-killer-cell surveillance and therapy of cancer.

Authors:  Mark J Smyth; Yoshihiro Hayakawa; Kazuyoshi Takeda; Hideo Yagita
Journal:  Nat Rev Cancer       Date:  2002-11       Impact factor: 60.716

2.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

Review 3.  Pathways to melanoma development: lessons from the mouse.

Authors:  Graeme J Walker; Nicholas K Hayward
Journal:  J Invest Dermatol       Date:  2002-10       Impact factor: 8.551

Review 4.  HLA expression in uveal melanoma: there is no rule without some exception.

Authors:  Martine J Jager; H Monique H Hurks; Jelena Levitskaya; Rolf Kiessling
Journal:  Hum Immunol       Date:  2002-06       Impact factor: 2.850

5.  Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis.

Authors:  Juan A Recio; Frances P Noonan; Hisashi Takayama; Miriam R Anver; Paul Duray; Walter L Rush; Gerd Lindner; Edward C De Fabo; Ronald A DePinho; Glenn Merlino
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

6.  The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent.

Authors:  M J Smyth; M Taniguchi; S E Street
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

7.  In vivo natural killer cell activities revealed by natural killer cell-deficient mice.

Authors:  S Kim; K Iizuka; H L Aguila; I L Weissman; W M Yokoyama
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

8.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

Review 9.  Natural killer cell activation in mice and men: different triggers for similar weapons?

Authors:  Francesco Colucci; James P Di Santo; Paul J Leibson
Journal:  Nat Immunol       Date:  2002-09       Impact factor: 25.606

10.  Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1.

Authors:  Gili G Halfteck; Moran Elboim; Chamutal Gur; Hagit Achdout; Hormas Ghadially; Ofer Mandelboim
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

View more
  139 in total

1.  IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Authors:  Joe-Marc Chauvin; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Richelle DeBlasio; Cindy Sanders; Jiajie Hou; Xian-Yang Li; Soldano Ferrone; Diwakar Davar; John M Kirkwood; Robert J Johnston; Alan J Korman; Mark J Smyth; Hassane M Zarour
Journal:  Clin Cancer Res       Date:  2020-06-26       Impact factor: 12.531

2.  Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells.

Authors:  Sebastian Seth; Quan Qiu; Simon Danisch; Michael K Maier; Asolina Braun; Inga Ravens; Niklas Czeloth; Rebecca Hyde; Oliver Dittrich-Breiholz; Reinhold Förster; Günter Bernhardt
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

3.  Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time.

Authors:  D Fruci; M Benevolo; L Cifaldi; S Lorenzi; E Lo Monaco; E Tremante; P Giacomini
Journal:  Curr Oncol       Date:  2012-02       Impact factor: 3.677

4.  NK cells control breast cancer and related cancer stem cell hematological spread.

Authors:  Rossana Tallerico; Laura Conti; Stefania Lanzardo; Rosa Sottile; Cinzia Garofalo; Arnika K Wagner; Maria H Johansson; Costanza Maria Cristiani; Klas Kärre; Ennio Carbone; Federica Cavallo
Journal:  Oncoimmunology       Date:  2017-02-23       Impact factor: 8.110

5.  The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.

Authors:  Christopher J Chan; Ludovic Martinet; Susan Gilfillan; Fernando Souza-Fonseca-Guimaraes; Melvyn T Chow; Liam Town; David S Ritchie; Marco Colonna; Daniel M Andrews; Mark J Smyth
Journal:  Nat Immunol       Date:  2014-03-23       Impact factor: 25.606

6.  Intratumoral natural killer cells show reduced effector and cytolytic properties and control the differentiation of effector Th1 cells.

Authors:  Sourav Paul; Neeraja Kulkarni; Girdhari Lal
Journal:  Oncoimmunology       Date:  2016-09-20       Impact factor: 8.110

Review 7.  Taming killer cells may halt diabetes progression.

Authors:  Francesco Colucci; Corrado M Cilio
Journal:  Nat Immunol       Date:  2010-02       Impact factor: 25.606

8.  CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

Authors:  Amelia Roman Aguilera; Viviana P Lutzky; Deepak Mittal; Xian-Yang Li; Kimberley Stannard; Kazuyoshi Takeda; Günter Bernhardt; Michele W L Teng; William C Dougall; Mark J Smyth
Journal:  Oncoimmunology       Date:  2018-02-01       Impact factor: 8.110

9.  IL12-mediated sensitizing of T-cell receptor-dependent and -independent tumor cell killing.

Authors:  Matthias Braun; Marie L Ress; Young-Eun Yoo; Claus J Scholz; Matthias Eyrich; Paul G Schlegel; Matthias Wölfl
Journal:  Oncoimmunology       Date:  2016-05-19       Impact factor: 8.110

10.  Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.

Authors:  Conor J Kearney; Kelly M Ramsbottom; Ilia Voskoboinik; Phillip K Darcy; Jane Oliaro
Journal:  Oncoimmunology       Date:  2016-06-27       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.